Intas & Accord signs Agreement to acquire Prothya Biosolutions
This proposed acquisition marks a significant step in Intas and Accord's long-standing ambition to establish a global presence in the PDMP market, expanding Intas's established leadership in India into a truly international footprint.
Prothya Biosolutions, with primary operations in Amsterdam and Brussels and plasma collection centres across Hungary , employs approximately 1,200 people. The company is one of Europe's largest plasma fractionators. Formed in 2021 through the integration of Plasma Industries Belgium, originally linked to the Belgian Red Cross, and Sanquin Plasma Products, formerly a part of the Sanquin Blood Supply Foundation, Prothya brings over 60 years of experience in plasma collection and the development of PDMPs.
Binish Chudgar , Chairman of Intas & Accord, stated:
"We are delighted to expand our plasma business through the acquisition of Prothya Biosolutions. Combined with our fractionation capabilities in India , this positions us to create a truly global plasma platform—serving patients worldwide with critical, often under-prescribed, therapies."
Intas's plasma division in India has been supplying hospitals with PDMPs since 2015, supported by an annual fractionation capacity of over 1 million litres and exports to multiple international markets. Additional capacity is due to come online with the expansion of Intas's Gujarat-based facility.
Nir Epstein , CEO of Prothya, commented:
"Over the past four years, we've expanded into new markets, advanced critical therapies, established our own plasma collection network in Hungary , and supplied plasma derivatives to some of the world's leading PDMP companies—all while building a stronger, more resilient organization. I want to thank our dedicated team for their unwavering commitment to our patients. I believe Accord is the right company to support Prothya and its people in the next phase of growth and global expansion."
The global market for PDMPs—particularly IVIG (intravenous immunoglobulin)—is currently valued at $30 billion and is expected to reach $50 billion by 2035. This acquisition will give Intas access to significant additional fractionation capacity, supported by Accord's commercial footprint spanning 85 countries.
BofA Securities is acting as the exclusive financial advisor to Accord in this transaction.
Evercore is acting as the exclusive financial advisor to Prothya in this transaction.
About Intas:
Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical company based in Ahmedabad, India , having end-to-end capabilities of formulation development, manufacturing, and marketing along with backward integration of APIs.
Intas also has strong in-house biosimilar development and marketing capabilities, with more than 15 products being marketed. Intas is committed to expanding global healthcare access by providing affordable, high-quality medications through strategic partnerships and extensive R&D investment to meet the diverse needs of healthcare systems around the world. Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare, to operate in global markets.
Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America , Europe , Central & Latin America , Asia-Pacific as well as CIS and MENA countries. Intas's remarkable success in North America and European operations has helped us emerge as a global brand in the world's largest pharmaceutical markets.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
22 minutes ago
- CTV News
ATB remains ‘committed' to energy industry after Cormark acquisition, CEO says
Curtis Stange, President and Chief Executive Officer of ATB Financial, joins BNN Bloomberg to discuss working with Cormark as the company acquires the investment bank. Sorry, we're having trouble with this video. Please try again later. [5006/404] The head of ATB Financial says the Calgary-based financial institution will continue to focus on supporting Canada's energy industry following the announcement of a major acquisition. 'We are very committed to the energy industry in Western Canada and more broadly, Canada,' Curtis Stange, president and CEO of ATB, told BNN Bloomberg in a Tuesday interview. 'If you compare how we put our balance sheet to work; the percentage of our balance sheet as a total percentage of our total assets, it is meaningfully higher than any of the other banks in Canada… we are long on the energy industry. Stange's comments came a day after ATB said it would acquire all outstanding shares of independent investment bank Cormark Securities, which has offices in Toronto and Calgary. Financial terms of the deal were not disclosed. The agreement will combine Cormark with ATB's growing capital markets business, which Stange said has delivered results in recent years that the firm is 'quite pleased' with. 'We felt that an acquisition of this size was something that was in our future. We've been talking to the Cormark team… for eight to 12 months now and we're very happy with the announcement from yesterday,' he said. 'We have complimentary sectors… we are very focused on energy and diversifying, and Cormark has a very good mining business and a very successful diversified business we think we're going to unpack. We think there's great opportunity and great synergies between the two firms.' ATB, an Alberta Crown corporation, is optimistic about the growth of the Canadian economy and how its latest acquisition puts it in position to benefit from an increasing focus on nation building and self-sufficiency given the changing international trade landscape, Stange said. 'We think for the Canadian economy, we see some reasonable growth. We certainly see reasonable growth in Western Canada,' he said. 'Cormark has a client base that is quite diversified, similar to ATB. We think the flow of capital and bringing buyers and sellers together in the sectors that we're very specified in right now in addition to where we're going to focus will be a good thing for the Canadian economy, there's no doubt.'
Globe and Mail
22 minutes ago
- Globe and Mail
Apple Rises 9% in a Month: Buy, Sell or Hold the AAPL Stock?
Apple AAPL shares have risen 8.9% in the past month, driven by strong third-quarter fiscal 2025 results and a steady outlook despite tariff-related headwinds. Since the results announced on July 31, AAPL shares have appreciated 9.4%. Since Aug. 6's announcement of increasing U.S. investments to $600 billion, Apple shares have climbed 6.5%. Apple is benefiting from the growing adoption of Apple Intelligence that is infused across iPhone, Mac, and iPad. The company reported record June quarter revenues in more than two dozen countries and regions, including the United States, Canada, Latin America, Western Europe, the Middle East, India and South Asia. The robust performance was driven by double-digit growth across iPhone (13.5% year over year), Mac (14.8% year over year) and Services (13.3% year over year). For iPhone, Apple saw double-digit growth in emerging markets, including India, the Middle East, South Asia and Brazil. Services grew double-digit in both developed and emerging markets. Apple Intelligence is playing a key role in driving this growth thanks to the addition of more than 20 features that include visual intelligence, cleanup and powerful writing tools. Although Apple continues to play catch-up in the AI domain against Amazon AMZN, Microsoft MSFT, and Alphabet GOOGL, the third-quarter 2025 results reflect encouraging progress. Year to date (YTD), Apple shares are down 9.2%, underperforming the broader Zacks Computer and Technology sector's return of 13.5% and the trio. YTD, Microsoft, Alphabet, and Amazon shares have appreciated 23.8%, 6.2% and 0.9%, respectively. Apple Stock's YTD Performance AAPL shares are now trading above the 50-day and 200-day moving averages, indicating a bullish trend. Apple Trades Above 50-day and 200-day SMAs Apple Intelligence Features to boost AAPL Stock's Prospects In April, Apple expanded the availability of Apple Intelligence with iOS 18.4, iPadOS 18.4, and macOS Sequoia 15.4 updates in new languages, including French, German, Italian, Portuguese (Brazil), Spanish, Japanese, Korean, and Chinese (simplified), as well as localized English for Singapore and India. At the end of 2025, Apple Intelligence will be available in eight more languages: Danish, Dutch, Norwegian, Portuguese, Swedish, Turkish, Chinese (traditional) and Vietnamese. At this year's annual Worldwide Developers Conference, Apple announced new Apple Intelligence features like Live Translation, updates to visual intelligence, as well as enhancements to Image Playground and Genmoji. Shortcuts can access Apple Intelligence directly. Developers also get access to the on-device large language model, which is at the core of Apple Intelligence. The latest features are now available for testing and are expected to be generally available this fall with supported devices. Apple is expanding Services with AutoMix and Lyrics Translation features in Apple Music. Sing will allow users to transform their iPhones into a handheld microphone for Apple TV, while preferred routes and visited places in Apple Map make navigation easier for users. Apple Intelligence is now getting added to Apple Wallet, and users can make purchases with Apple Pay. Powered by Apple Intelligence, Apple Wallet can now automatically identify, summarize and display order tracking details from emails sent from merchants or delivery carriers. Meanwhile, Apple Pay expands the ability to pay with rewards and installments to in-store purchases for added flexibility and choice. Apple's U.S. Investments to Appease Trump, Escape Tariffs Apple now plans to spend $600 billion across the United States over the next four years. The plan includes the American Manufacturing Program (AMP), which is dedicated to bringing more of Apple's supply chain and advanced manufacturing to the U.S. AMP partners include Corning, Coherent, GlobalWafers America, Applied Materials, Texas Instruments, Samsung, GlobalFoundries, Amkor and Broadcom. Apple currently partners with thousands of suppliers across all 50 states in the U.S., supporting more than 450,000 supplier and partner jobs. In the next four years, AAPL plans to directly hire 20,000 people in the U.S. in roles including research and development, silicon engineering, software development, and AI and machine learning. Apple's accelerating U.S. investments are expected to appease U.S. President Donald Trump, who has criticized the iPhone maker's strategy of manufacturing iPhones sold in the United States in other countries, including India. The latest announcement is expected to help Apple escape potential tariff threats. Tariffs are currently expected to have a negative impact of roughly $1.1 billion in the fourth quarter of fiscal 2025. Apple expects gross margin between 46% and 47% for the current quarter compared with a gross margin of 46.5% in the fiscal third quarter. Apple's Q4 Revenues to Grow Amid Tariff Threats Apple expects the September quarter's (fourth-quarter fiscal 2025) net sales to grow mid to high single digits on a year-over-year basis. The company expects the Services year-over-year growth rate to be similar to that of the June quarter. The Zacks Consensus Estimate for Apple's fourth-quarter fiscal 2025 revenues is pegged at $100.37 billion, indicating 5.73% growth over the figure reported in the year-ago quarter. The consensus mark for earnings has increased 8.1% to $1.73 per share over the past 30 days, indicating 5.5% growth from the figure reported in the year-ago quarter. Apple Shares are Overvalued AAPL stock is not so cheap, as the Value Score of F suggests a stretched valuation at this moment. Apple is trading at a forward 12-month Price/Sales (P/S) of 7.93X compared with the sector's 6.78X, Amazon's 3.14X and Alphabet's 6.79X. However, Microsoft's P/S of 11.91 is higher than Apple. Price/Sales (F12M) Conclusion Apple is expected to benefit from growing adoption of Apple Intelligence and expanding features. The company's investments in expanding its manufacturing footprint in the United States are expected to help lower tariff-related headaches. Investors already holding AAPL shares should continue to do so based on these factors. However, stretched valuation is a concern for prospective investors. AAPL currently has a Zacks Rank #3 (Hold), suggesting that it may be wise to wait for a more favorable entry point in the stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Inc. (AMZN): Free Stock Analysis Report Apple Inc. (AAPL): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report
Globe and Mail
2 hours ago
- Globe and Mail
PL Developments Builds a Smarter, Healthier Supply Chain with Kinaxis
Kinaxis ® (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced that PL Developments (PLD), a leading manufacturer and distributer of over-the-counter pharmaceuticals and healthcare products, has selected the Kinaxis Maestro™ platform to meet growing demand from consumers and major U.S. retailer partners. By replacing manual tools and spreadsheets with AI-powered orchestration and predictive planning, PLD will accelerate the delivery of essential healthcare products with greater agility, accuracy and efficiency. Specializing in end-to-end solutions from product development to distribution, PLD supplies some of the largest retailers in the U.S. including Walmart, Walgreens, CVS, Costco, Sam's Club and Target with health and wellness products in categories including analgesics, cough/cold, allergy and digestive. Due to market expansion and rapidly increasing consumer demand for accessible and affordable healthcare products, PLD needed to deliver to its retail partners with greater speed, accuracy and responsiveness. With manual planning tools and siloed decision-making, PLD was challenged by limited visibility across its operations leading to delayed order confirmations and high inventory levels. To maintain its position as a trusted industry leader, PLD needed a next-generation supply chain platform to meet evolving customer expectations while continuing to deliver on the promise of quality at every step. After rigorous evaluation, Maestro stood out for its unmatched ability to unify data and provide real-time insights, enabling predictive planning to anticipate demand. Maestro allows PLD to optimize inventory, respond faster to market shifts and scale execution across every function of the business with fewer resources and greater supply chain visibility. 'Consumers expect fast access to trusted health and wellness products, and our retail partners need the inventory to match shifting demand,' s aid Thomas Crowe, chief supply chain officer at PL Developments. 'With Maestro, we can anticipate this demand, simulate scenarios, plan for market shifts and make confident, data-driven decisions in minutes. It's a game changer that empowers our team to deliver the innovation and products consumers rely on every single day and Kinaxis is now a key part of that innovation.' 'PLD is a prime example of a forward-thinking manufacturer embracing the speed and intelligence today's healthcare supply chains demand,' said Mark Morgan, president of global commercial operations at Kinaxis. 'With Maestro, they're not just replacing spreadsheets, they're unlocking real-time visibility, rapid execution and scalable decision making. We're proud to support PLD as they deliver the trusted healthcare products consumers rely on, faster and more efficiently than ever.' To learn more about Kinaxis and its supply chain management solutions, please visit About Kinaxis Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them, in service of humanity. Our powerful, AI-infused supply chain orchestration platform, Maestro™ combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today's volatility and disruption. For more news and information, please visit or follow us on LinkedIn.
